Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


17.06.2019

1 AJR Am J Roentgenol
4 Anticancer Res
2 BMC Cancer
1 Br J Radiol
2 Cancer
1 Cancer Imaging
1 Cancer Res
1 Endocrinology
1 Eur Radiol
4 Eur Urol
1 Int J Cancer
4 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 Invest Radiol
1 J Nucl Med
2 J Urol
1 Mod Pathol
1 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A
5 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. SADOUGHI N, Krishna S, McInnes MDF, Flood TA, et al
    ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasound-Guided Biopsy.
    AJR Am J Roentgenol. 2018 Jul 11:W1-W8. doi: 10.2214/AJR.17.18958.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. KOBAYASHI T, Namitome R, Hirata YU, Shiota M, et al
    Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer.
    Anticancer Res. 2019;39:3191-3195.
    PubMed     Text format     Abstract available

  3. DRUDI FM, Cantisani V, Angelini F, Ciccariello M, et al
    Multiparametric MRI Versus Multiparametric US in the Detection of Prostate Cancer.
    Anticancer Res. 2019;39:3101-3110.
    PubMed     Text format     Abstract available

  4. ITO T, Kanao K, Takahara K, Ando R, et al
    Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2019;39:3089-3094.
    PubMed     Text format     Abstract available

  5. DROBKOVA H, Jurecekova J, Sivonova MK, Mazuchova J, et al
    Associations Between Gene Polymorphisms of Vascular Endothelial Growth Factor and Prostate Cancer.
    Anticancer Res. 2019;39:2903-2909.
    PubMed     Text format     Abstract available


    BMC Cancer

  6. KOSAKA T, Hongo H, Oya M
    Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    BMC Cancer. 2019;19:562.
    PubMed     Text format     Abstract available

  7. KAPOOR R, Deek MP, McIntyre R, Raman N, et al
    A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    BMC Cancer. 2019;19:572.
    PubMed     Text format     Abstract available


    Br J Radiol

  8. SUREKA B, Elhence P, Khera PS, Choudhary GR, et al
    Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.
    Br J Radiol. 2019 Jun 11:20190181. doi: 10.1259/bjr.20190181.
    PubMed     Text format     Abstract available


    Cancer

  9. SHIRAZIPOUR CH, Freedland SJ
    Obesity, visceral adiposity, and prostate cancer: What is the role of lifestyle interventions?
    Cancer. 2019 Jun 10. doi: 10.1002/cncr.32165.
    PubMed     Text format    

  10. DICKERMAN BA, Torfadottir JE, Valdimarsdottir UA, Giovannucci E, et al
    Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study.
    Cancer. 2019 Jun 10. doi: 10.1002/cncr.32167.
    PubMed     Text format     Abstract available


    Cancer Imaging

  11. DAMJANOVIC J, Janssen JC, Prasad V, Diederichs G, et al
    (68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer.
    Cancer Imaging. 2019;19:37.
    PubMed     Text format     Abstract available


    Cancer Res

  12. GAO Y, Chen L, Du Z, Gao W, et al
    Glutamate decarboxylase 65 signals through the androgen receptor to promote castration resistance in prostate cancer.
    Cancer Res. 2019 Jun 10. pii: 0008-5472.CAN-19-0700.
    PubMed     Text format     Abstract available


    Endocrinology

  13. LEE GT, Kim JH, Kwon SJ, Stein MN, et al
    Dihydrotestosterone increases cytotoxic activity of macrophages on prostate cancer cells via TRAIL.
    Endocrinology. 2019 Jun 11. pii: 5512657. doi: 10.1210/en.2019-00367.
    PubMed     Text format     Abstract available


    Eur Radiol

  14. ANTONELLI M, Johnston EW, Dikaios N, Cheung KK, et al
    Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.
    Eur Radiol. 2019 Jun 11. pii: 10.1007/s00330-019-06244.
    PubMed     Text format     Abstract available


    Eur Urol

  15. BERG S, Cole A, Trinh QD
    Reply to Michael Froehner and Christian Thomas's Letter to the Editor re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in P
    Eur Urol. 2019 Jun 4. pii: S0302-2838(19)30447.
    PubMed     Text format    

  16. EFSTATHIOU E, Davis JW, Pisters L, Li W, et al
    Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30414.
    PubMed     Text format     Abstract available

  17. ISAACSSON VELHO P, Fu W, Wang H, Mirkheshti N, et al
    Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30439.
    PubMed     Text format     Abstract available

  18. MONTIRONI R, Cheng L, Scarpelli M, Cimadamore A, et al
    Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
    Eur Urol. 2019 Jun 5. pii: S0302-2838(19)30442.
    PubMed     Text format    


    Int J Cancer

  19. BOWDEN P, See AW, Frydenberg M, Haxhimolla H, et al
    Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: interim outcomes of a prospective clinical trial.
    Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32509.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  20. JACKSON IL, Pavlovic R, Alexander AA, Connors CQ, et al
    BIO 300, a nanosuspension of genistein, mitigates radiation-induced erectile dysfunction and sensitizes human prostate cancer xenografts to radiation therapy.
    Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30816.
    PubMed     Text format     Abstract available

  21. GREWAL AS, Schonewolf C, Min EJ, Chao HH, et al
    Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 11. pii: S0360-3016(19)30827.
    PubMed     Text format     Abstract available

  22. LEUFGENS F, Berneking V, Vogeli TA, Kirschner-Hermanns R, et al
    Quality of life changes >10 years following postoperative radiotherapy after radical prostatectomy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30829.
    PubMed     Text format     Abstract available

  23. YOSHIDA S, Takahara T, Arita Y, Ishii C, et al
    Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor.
    Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30837.
    PubMed     Text format     Abstract available


    Int J Urol

  24. HONGO F, Okihara K, Kitamura K, Fujihara A, et al
    Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
    Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14037.
    PubMed     Text format     Abstract available

  25. ITO K, Oki R, Sekine Y, Arai S, et al
    Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.
    Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14039.
    PubMed     Text format     Abstract available


    Invest Radiol

  26. ARITA Y, Takahara T, Yoshida S, Kwee TC, et al
    Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging.
    Invest Radiol. 2019 May 21. doi: 10.1097/RLI.0000000000000579.
    PubMed     Text format     Abstract available


    J Nucl Med

  27. ROWE SP, Campbell SP, Mana-Ay M, Szabo Z, et al
    Prospective Evaluation of PSMA-Targeted (18)F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    J Nucl Med. 2019 Jun 14. pii: jnumed.119.226514. doi: 10.2967/jnumed.119.226514.
    PubMed     Text format     Abstract available


    J Urol

  28. MARGEL D, Peer A, Ber Y, Shavit-Grievink L, et al
    Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease.
    J Urol. 2019 Jun 12:101097JU0000000000000384. doi: 10.1097/JU.0000000000000384.
    PubMed     Text format     Abstract available

  29. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000379. doi: 10.1097/JU.0000000000000379.
    PubMed     Text format    


    Mod Pathol

  30. MIYAI K, Mikoshi A, Hamabe F, Nakanishi K, et al
    Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer.
    Mod Pathol. 2019 Jun 7. pii: 10.1038/s41379-019-0292.
    PubMed     Text format     Abstract available


    Oncol Rep

  31. MURAMATSU H, Sumitomo M, Morinaga S, Kajikawa K, et al
    Targeting lactate dehydrogenaseA promotes docetaxelinduced cytotoxicity predominantly in castrationresistant prostate cancer cells.
    Oncol Rep. 2019 May 24. doi: 10.3892/or.2019.7171.
    PubMed     Text format     Abstract available


    PLoS One

  32. PALSDOTTIR T, Nordstrom T, Aly M, Lindberg J, et al
    Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.
    PLoS One. 2019;14:e0218280.
    PubMed     Text format     Abstract available

  33. ZECHMANN S, Di Gangi S, Kaplan V, Meier R, et al
    Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) - A retrospective study.
    PLoS One. 2019;14:e0217879.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A


  34. Correction for Lorenzo et al., Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth.
    Proc Natl Acad Sci U S A. 2019 Jun 10. pii: 1908514116.
    PubMed     Text format    


    Urology

  35. MARTIN SE, Begun EM, Samir E, Azaiza MT, et al
    Incidence and Morbidity of Radiation-Induced Hemorrhagic Cystitis in Prostate Cancer.
    Urology. 2019 Jun 12. pii: S0090-4295(19)30513.
    PubMed     Text format     Abstract available

  36. STEINBERG RL, Johnson BA, Cadeddu JA
    Magnetic-assisted Robotic Surgery to Facilitate Reduced-port Radical Prostatectomy.
    Urology. 2019;126:237.
    PubMed     Text format     Abstract available

  37. LAN T, Chen Y, Su Q, Ye J, et al
    Oncological outcome of cytoreductive radical prostatectomy in prostate cancer patients with bone oligometastases.
    Urology. 2019 Jun 7. pii: S0090-4295(19)30507.
    PubMed     Text format     Abstract available

  38. JACOBS BL, Lopa SH, Yabes JG, Nelson JB, et al
    Change in functional status after prostate cancer treatment among Medicare Advantage beneficiaries.
    Urology. 2019 Jun 7. pii: S0090-4295(19)30508.
    PubMed     Text format     Abstract available

  39. HOFFMANN MA, Wieler HJ, Baues C, Kuntz NJ, et al
    Letter-to-the-Editor Reply: "The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer": "68Ga Scatter Correction to Eliminate Halo-Artifacts in PET Imaging".
    Urology. 2019 Jun 11. pii: S0090-4295(19)30517.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: